Rituximab for Ocular Inflammatory Disease

References

• Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179–199. doi:10.1038/s41573-020-00092-2.
   PubMed Web of Science ®Google Scholar
• Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14(12):2820–2841. doi:10.1080/21645515.2018.1508624.
   PubMed Web of Science ®Google Scholar
• Lee AYS. CD20+ T cells: an emerging T cell subset in human pathology. Inflamm Res. 2022 Aug 11. doi:10.1007/s00011-022-01622-x.
   Web of Science ®Google Scholar
• Pavlasova G, Mraz M. The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494–1506. doi:10.3324/haematol.2019.243543.
   PubMed Web of Science ®Google Scholar
• Delate T, Hansen ML, Gutierrez AC, Le KN. Indications for rituximab use in an integrated health care delivery system. J Manag Care Spec Pharm. 2020;26(7):832–838. doi:10.18553/jmcp.2020.26.7.832.
   PubMed Web of Science ®Google Scholar
• Sarsour K, Beckley-Kartey S, Melega S, et al. Rituximab utilization for approved and off-label nononcology indications and patients’ experiences with the patient alert card. Pharmacol Res Perspect. 2020 Jan 3;8(1):e00555. doi:10.1002/prp2.555.
   PubMed Web of Science ®Google Scholar
• Ng CC, Sy A, Cunningham ET Jr. Rituximab for non-infectious Uveitis and Scleritis. J Ophthalmic Inflamm Infect. 2021 Aug 16;11(1):23. doi:10.1186/s12348-021-00252-4.
   PubMed Web of Science ®Google Scholar
• Vergouwen DPC, van Laar JAM, Ten Berge JC, Ramdas WD, Rothova A. Efficacy and maintenance of rituximab treatment in non-infectious scleritis. Acta Ophthalmol. 2022 May;100(3):e861–e863. doi:10.1111/aos.14939.
   PubMed Web of Science ®Google Scholar
• Ng CC, Sy A, Cunningham ET Jr. Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease. J Ophthalmic Inflamm Infect. 2021 Aug 27;11(1):24. doi:10.1186/s12348-021-00253-3.
   PubMed Web of Science ®Google Scholar
• Kang S, Hamed Azzam S, Minakaran N, Ezra DG. Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev. 2022 Jun 16;6(6):CD009226. doi:10.1002/14651858.CD009226.pub3.
   PubMedGoogle Scholar
• Ostrowski RA, Bussey MR, Shayesteh Y, Jay WM. Rituximab in the treatment of thyroid eye disease: a review. Neuroophthalmology. 2015;39(3):109–115. doi:10.3109/01658107.2015.1039140.
   PubMed Web of Science ®Google Scholar
• Bolletta E, Gozzi F, Mastrofilippo V, et al. Efficacy of rituximab treatment in Vogt-Koyanagi-Harada disease poorly controlled by traditional immunosuppressive treatment. Ocul Immunol Inflamm. 2021 Apr;1:1–6. doi:10.1080/09273948.2021.1880604.
   Google Scholar
• Daldal H, Nazıroğlu M. Rituximab attenuated lipopolysaccharide-induced oxidative cytotoxicity, apoptosis, and inflammation in the human retina cells via modulating the TRPM2 signaling pathways. Ocul Immunol Inflamm. 2022 May;19:1–14. doi:10.1080/09273948.2022.2075400.
   Google Scholar
• Vergouwen DPC, Ten Berge JC, Naus-Postema NC, Rothova A. Subconjunctival rituximab administration for the treatment of scleritis. Ocul Immunol Inflamm. 2022 Feb;16:1–3. doi:10.1080/09273948.2022.2029498.
   Google Scholar
• Mehta K, Gujjar AP, Babu K. Peripheral ulcerative keratitis in a young lady with systemic lupus erythematosus post rituximab infusion-A case report. Ocul Immunol Inflamm. 2022 Feb;25:1–3. doi:10.1080/09273948.2022.2037654.
   Google Scholar
• Abu El-Asrar AM, Dheyab A, Khatib D, Struyf S, Van Damme J, Opdenakker G. Efficacy of B cell depletion therapy with rituximab in refractory chronic recurrent uveitis associated with vogt-koyanagi-harada disease. Ocul Immunol Inflamm. 2022;30(3):750–757. doi:10.1080/09273948.2020.1820531.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Van Damme J, Struyf S, Opdenakker G. New perspectives on the immunopathogenesis and treatment of uveitis associated with vogt-koyanagi-harada disease. Front Med (Lausanne). Nov 12 2021;8:705796. doi:10.3389/fmed.2021.705796.
   PubMed Web of Science ®Google Scholar
• Umran RMR, Shukur ZYH. Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease. Mod Rheumatol. 2018;28(1):197–199. doi:10.3109/14397595.2015.1071234.
   PubMed Web of Science ®Google Scholar
• Umran RMR, Shukur ZYH. Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease. Mod Rheumatol. 2018;28:197–199.
   PubMed Web of Science ®Google Scholar
• Caso F, Rigante D, Vitale A, et al. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clin Rheumatol. 2015;34(10):1817–1820. doi:10.1007/s10067-014-2781-1.
   PubMed Web of Science ®Google Scholar
• Dolz-Marco R, Gallego-Pinazo R, Díaz-Llopis M. Rituximab in refractory Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. 2011;1(4):177–180. doi:10.1007/s12348-011-0027-9.
   PubMedGoogle Scholar
• Cunningham ET Jr, Acharya N, Kempen JH, Zierhut M. Design and interpretation of clinic-based studies in uveitis. Ocul Immunol Inflamm. 2015;23(4):267–270. doi:10.3109/09273948.2015.1074028.
   PubMed Web of Science ®Google Scholar
• McGrath LA, Ryan DA, Warrier SK, Coupland SE, Glasson WJ. Conjunctival Lymphoma. Eye (Lond). 2022 Jul 26. doi:10.1038/s41433-022-02176-2.
   PubMed Web of Science ®Google Scholar
• Sura AA, McCallum RM. Peripheral ulcerative keratitis due to systemic diseases. Curr Opin Ophthalmol. 2022;33(6):543–550. doi:10.1097/ICU.0000000000000895.
   PubMed Web of Science ®Google Scholar
• Hassanpour K, ElSheikh H, Arabi R, et al. Peripheral ulcerative keratitis: a review. J Ophthalmic Vis Res. 2022;17(2):252–275. doi:10.18502/jovr.v17i2.10797.
   PubMedGoogle Scholar
• Desbois AC, Biard L, Sène D, et al. Rituximab-associated vasculitis flare: incidence, predictors, and outcome. J Rheumatol. 2020;47(6):896–902. doi:10.3899/jrheum.190076.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial. JAMA Ophthalmol. 2014;132(5):572–578. doi:10.1001/jamaophthalmol.2013.8179.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121(10):1885–1891. doi:10.1016/j.ophtha.2014.04.044.
   PubMed Web of Science ®Google Scholar
• Kaegi C, Wuest B, Crowley C, Boyman O. Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders. Front Immunol. Feb 2 2022;12:788830. doi:10.3389/fimmu.2021.788830.
   PubMed Web of Science ®Google Scholar
• Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017 Nov 16;8(1):12. doi:10.1007/s13317-017-0100-y.
   PubMed Web of Science ®Google Scholar